Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

Healthcare Medical Devices
SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

SQI Diagnostics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(494)
•••
Post by FactFinder1994on May 23, 2023 9:10am
108 Views
Post# 35459960

SQI & UHN Partner (LBE) will trrive with TOR-Dx.

SQI & UHN Partner (LBE) will trrive with TOR-Dx. Those with intimate knowledge understand the great value of SQI's multiplex diagnostics, bringing forward high quality data with which to act on in minutes.  Game changing applications.  LBE has made the investments and is ready to push forward, and UHN & SQI are there to drive and support greater adoption.    

Lung Bioengineering Inc. (LBE) has established the first centralized ex vivo lung perfusion service model in the United States. LBE’s service model is driven by data and powered by the expertise of our clinical teams. Our model simplifies the journey from allocation to transplant, with a goal of expanding the utilization of transplantable lungs. Our team of specialists is available 24/7 to unify key touchpoints throughout each case to provide a seamless clinical experience and deliver results for our partners.

                                                                   ishlt.org • 2 min read WEBINAR: Modernizing Your Transplant Program with an Integrated EVLP Service                                                                                                 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities